MAP2K7 and neoplasm: He made the case for treating BRAF melanomas that have acquired MEK resistance with histone deacetylases—the metabolic compensation of tumour cells leaves them uniquely susceptible to the toxic levels of reactive oxygen species generated, whereas healthy host tissue remains intact.